My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

234.00 +1.64 (+0.71%)

Official Closing Price Updated: 7:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

89 90 Next >

3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More ↗

August 18, 2024

These stocks dividends continue to flow and grow.

Via The Motley Fool

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year ↗

August 18, 2024

This list of top-selling drugs could look drastically different in a few years.

Via The Motley Fool

3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income ↗

August 17, 2024

These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.

Via The Motley Fool

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

August 16, 2024

These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates

Via MarketBeat

Topics Artificial Intelligence Economy

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

Decoding AbbVie's Options Activity: What's the Big Picture? ↗

August 14, 2024

Via Benzinga

Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal ↗

August 12, 2024

Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.

Via Benzinga

The 3 Best Stocks to Buy to Survive Another S&P 500 Crash ↗

August 15, 2024

These three stocks to buy now will protect your portfolio if the S&P 500 crashes again regardless of whether there is a recession or not.

Via InvestorPlace

Topics Economy Stocks

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome ↗

August 13, 2024

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...

Via Benzinga

3 Stocks Retirees Should Absolutely Love ↗

August 10, 2024

All of these stocks can provide steady income to retired investors.

Via The Motley Fool

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

August 09, 2024

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

August 02, 2024

Via Benzinga

A Closer Look at AbbVie's Options Market Dynamics ↗

July 31, 2024

Via Benzinga

The Defensive Sectors And VIX Have NOT Given The All-Clear Signal ↗

August 08, 2024

The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture.

Via Talk Markets

Topics Stocks

Warren Buffett's Approach To Investing In Election Years ↗

August 07, 2024

Warren Buffett, known as the 'Oracle of Omaha', is a highly successful American investor who manages his portfolio consistently, regardless of elections or market conditions.

Via Benzinga

Elliott Wave Technical Analysis: AbbVie Inc. ↗

August 07, 2024

An in-depth look at ABBV's price movements using the Elliott Wave Theory, helping traders identify potential opportunities based on current trends and market structure.

Via Talk Markets

Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

August 06, 2024

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...

Via PressReach

AbbVie, Leidos, KKR And More On CNBC's 'Final Trades' ↗

August 06, 2024

Via Benzinga

Large Cap Biopharma And Healthcare, A Port In A Storm ↗

August 05, 2024

Healthcare and biopharma show nice gains in a volatile week.

Via Talk Markets

Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever. ↗

August 05, 2024

Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.

Via The Motley Fool

8 Health Care Stocks With Whale Alerts In Today's Session ↗

August 01, 2024

Via Benzinga

Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early ↗

July 31, 2024

The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss.

Via Investor's Business Daily

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗

July 31, 2024

Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.

Via InvestorPlace

7 Stocks Set for a Major Bull Run ↗

July 31, 2024

Explore top stocks to buy, leading in social media, semiconductors, entertainment, restaurants, payments and biotechnology.

Via InvestorPlace

3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle ↗

July 31, 2024

Here are three powerhouse growth stocks long-term investors may want to hone in on during this part of the market cycle.

Via InvestorPlace

Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗

July 30, 2024

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.

Via Benzinga

AbbVie Analysts Lead the Stock Higher as Humira Worries Recede

July 30, 2024

AbbVie had a solid quarter, accelerating growth and giving positive guidance that has analysts lifting their price targets and the stock advancing.

Via MarketBeat

Topics Earnings Intellectual Property

Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity

July 30, 2024

Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip

Via MarketBeat

3 High-Yield Dividend Stocks That Are Looking Super Hot ↗

July 29, 2024

Discover high-yield dividend stocks offering solid returns. Learn about AbbVie, Target, and Abbott for reliable income and growth potential.

Via InvestorPlace

3 Dividend-Paying ETFs to Secure Your Passive Income Stream ↗

July 29, 2024

Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs?

Via InvestorPlace

Topics ETFs

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

89 90 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.